带 Siri 集成的连续血糖监测器可改善糖尿病失明患者的血糖控制。
Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes.
机构信息
Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
出版信息
Diabetes Technol Ther. 2021 Jan;23(1):81-83. doi: 10.1089/dia.2020.0320. Epub 2020 Jul 30.
Continuous glucose monitoring (CGM) is safe and effective in improving glycemic control in insulin-treated patients with diabetes. However, the safety of CGM use in legally blind patients with diabetes is unknown. This is a retrospective study of seven legally blind patients with diabetes on intensive insulin therapy who were using Dexcom G6 with voice-enabled Apple's Siri feature. CGM metrics, hemoglobin A1c, and frequency of severe hypoglycemia were measured for 12 months. There was a significant reduction in A1c after 3, 6, and 12 months of Dexcom G6 with Apple Siri use ( < 0.0001). Time-in-range increased at 12 months (50.9% ± 5.5% at 3 months vs. 56.8% ± 5.5% at 12 months, = 0.029) without increase in time spent in hypoglycemia. There was a significant reduction in severe hypoglycemia requiring medical assistance for 12 months. Voice-enabled CGM use improved glycemic control and reduced severe hypoglycemia in legally blind patients with diabetes on intensive insulin therapy.
连续血糖监测 (CGM) 在改善接受胰岛素治疗的糖尿病患者的血糖控制方面是安全且有效的。然而，在患有糖尿病的法定盲人中使用 CGM 的安全性尚不清楚。这是一项回顾性研究，纳入了七名正在接受强化胰岛素治疗且患有糖尿病的法定盲人患者，他们使用带语音功能的 Dexcom G6 和苹果的 Siri 功能。在 12 个月内测量了 CGM 指标、糖化血红蛋白和严重低血糖的发生频率。在使用 Dexcom G6 和苹果 Siri 三个月、六个月和十二个月后，糖化血红蛋白均显著降低（ < 0.0001）。在 12 个月时，时间在目标范围内的时间增加（3 个月时为 50.9%±5.5%，12 个月时为 56.8%±5.5%， = 0.029），而低血糖时间并未增加。在 12 个月时，需要医疗协助的严重低血糖显著减少。在接受强化胰岛素治疗的患有糖尿病的法定盲人患者中，带语音功能的 CGM 使用改善了血糖控制并减少了严重低血糖的发生。
Zotero 插件